A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
Latest Information Update: 08 Oct 2025
At a glance
- Drugs ST 400 (Primary) ; Busulfan; Plerixafor
- Indications Sickle cell anaemia
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Acronyms PRECIZN-1
- Sponsors Bioverativ
Most Recent Events
- 12 Sep 2025 Status changed from active, no longer recruiting to completed.
- 17 Nov 2023 Planned End Date changed from 9 Aug 2024 to 14 Jul 2025.
- 17 Nov 2023 Planned primary completion date changed from 9 Aug 2024 to 14 Jul 2025.